Immunocore Holdings plc (IMCR)
Market Cap | 2.46B |
Revenue (ttm) | 173.18M |
Net Income (ttm) | -49.67M |
Shares Out | 49.93M |
EPS (ttm) | -1.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 187,651 |
Open | 48.87 |
Previous Close | 47.52 |
Day's Range | 48.87 - 50.90 |
52-Week Range | 25.01 - 69.06 |
Beta | 0.61 |
Analysts | Buy |
Price Target | 82.72 (+67.5%) |
Earnings Date | May 10, 2023 |
About IMCR
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase... [Read more]
Financial Performance
In 2022, IMCR's revenue was 143.74 million, an increase of 441.99% compared to the previous year's 26.52 million. Losses were -41.22 million, -68.66% less than in 2021.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $82.72, which is an increase of 67.50% from the latest price.
News

Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

Immunocore to present four posters at AACR Annual Meeting 2023
Immunocore to present four posters at AACR Annual Meeting 2023

Immunocore Reports 2022 Financial Results and Provides Business Update
Immunocore Reports 2022 Financial Results and Provides Business Update

Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences

Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know
Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV

Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving hi...

Is Biotech Immunocore About To Make A 25% Price Move?
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc...

Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

3 Pharma Stocks That Will Mint Millionaires
In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB) climbed 6% so far this year.

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest...

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
Immunocore announces strategic priorities including pipeline expansion for 2023 - 2024

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
Immunocore to present at the 41 st Annual J . P . Morgan Healthcare Conference

Best Momentum Stocks to Buy for December 30th
IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.

New Strong Buy Stocks for December 30th
IMCR, RGA, LPLA, ACR and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2022.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR ...

3 Drug Stocks Most Wall Street Analysts Are Bullish About
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro e...

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Immunocore is awarded the Prix Galien France award for KIMMTRAK
Immunocore is awarded the Prix Galien France award for KIMMTRAK

Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 27% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 27.1% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upwa...

Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Immunocore p resents ovarian cancer expansion d ata for ImmTAC ® candidate IMC-C103C targeting MAGE-A4